文献速递炎症性肠病

综述:炎症性肠病疾病严重程度的测量——超越达标治疗

Review article: Measuring disease severity in inflammatory bowel disease - Beyond treat to target.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-01

本叙述性综述通过检索截至2024年3月1日的Medline全文文献,探讨成人炎症性肠病(IBD)疾病严重程度的概念。文章指出IBD疾病评估已从症状负担转向包含炎症指标、遗传、血清和蛋白质组学及生活质量等多维度评估,纵向研究提示疾病负担由疾病表型、复杂病程临床标志物、肠道炎症及IBD对患者的影响驱动。文章认为测量IBD严重程度可能比单一时间点肠道炎症更能全面反映疾病负担,并可能与纵向结局相关。

要点

  • IBD疾病评估已从症状负担扩展至炎症指标、遗传、血清和蛋白质组学及生活质量等多维度。
  • 复杂病程的临床标志物包括既往肠切除、皮质类固醇使用、CD肛周病变、UC近期住院。
  • 测量IBD严重程度可能比单一时间点肠道炎症更全面反映疾病负担并与纵向结局相关。

核心结论

  • IBD严重程度因影响因素众多而难以概念化,测量IBD严重程度可能比单一时间点肠道炎症更全面反映疾病负担,并可能与纵向结局相关。

研究设计与样本

  • 叙述性综述,通过Medline检索截至2024年3月1日可获取的全文文献,检索词涵盖疾病活动度评估、疾病严重程度、预后、克罗恩病(CD)和溃疡性结肠炎(UC)自然史及IBD负担。

主要发现

  • 当前IBD疾病评估方法已从关注症状负担演变至包含炎症靶点、遗传、血清和蛋白质组学特征以及生活质量、残疾和心理社会健康评估。
  • IBD纵向研究提示疾病负担由疾病表型、复杂病程临床标志物(既往肠切除、皮质类固醇使用、CD肛周病变、UC近期住院)、肠道炎症及IBD对患者的影响驱动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory bowel disease (IBD) follows a heterogenous disease course and predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and existing tools measure disease activity at a snapshot in time. Comprehensive assessment of IBD severity should incorporate disease activity, prognosis, and the impacts of disease on a patient. This review investigates the concept of disease severity in adults with IBD to highlight key components contributing to this. METHODS: To perform this narrative review, a Medline search was conducted for full-text articles available at 1st March 2024 using search terms which encompassed disease activity assessment, disease severity, prognosis, natural history of Crohn's disease (CD) and ulcerative colitis (UC), and the burden of IBD. RESULTS: Current methods of disease assessment in IBD have evolved from a focus on the burden of symptoms to one that includes inflammatory targets, genetic, serological, and proteomic profiles, and assessments of quality-of-life (QoL), disability, and psychosocial health. Longitudinal studies of IBD suggest that the burden of illness is driven by disease phenotype, clinical markers of complicated disease course (previous intestinal resection, corticosteroid use, perianal disease in CD, recent hospitalisations in UC), gut inflammation, and the impact of IBD on the patient. CONCLUSIONS: Disease severity in IBD can be difficult to conceptualise due to the multitude of factors that contribute to IBD outcomes. Measurement of IBD severity may better encapsulate the full burden of illness rather than gut inflammation alone at a single timepoint and may be associated with longitudinal outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Swaminathan A, Day AS, Sparrow MP, et al. Review article: Measuring disease severity in inflammatory bowel disease - Beyond treat to target. Aliment Pharmacol Ther. 2024. PMID: 39403053. doi:10.1111/apt.18231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。